BOSTON (CBS) — A decade of research finally reached its goal for Marlboro company Advanced Cell Technology.
The Food and Drug Administration (FDA) has given the company approval to conduct its first human study using embryonic stem cells to treat a rare genetic eye disorder that leads to blindness in children.
The FDA approval means Advanced Cell Technology will inject embryonic stem cells into the eyes of 12 young patients who suffer from Stargardt disease, the leading cause of blindness in children.
WBZ New England Business Editor Anthony Silva spoke with the company’s Chief Scientific Officer Dr. Robert Lanza.
Listen to Silva’s interview with Dr. Lanza.
The testing is expected to begin next year.